GSE153871 cytarabine U2OS 0 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE153871_cytarabine_U2OS_0_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE153871_cytarabine_U2OS_0_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE153871_cytarabine_U2OS_0_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE153871_cytarabine_U2OS_0_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

differentiation antagonizing non-protein coding RNA

Gene

GTP binding protein 6

Gene

SBDS pseudogene 1

Gene

long intergenic non-protein coding RNA 3007

Gene

eukaryotic translation elongation factor 1 gamma pseudogene 5

Gene

importin 8 pseudogene 1

Gene

MSI2 antisense RNA 1

Gene

ANKRD33B pseudogene 9

Gene

ribosomal protein L31 pseudogene 52

  • Gene

    valyl-tRNA synthetase 1


  • Gene

    differentiation antagonizing non-protein coding RNA


  • Gene

    GTP binding protein 6


  • Gene

    SBDS pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 3007


  • Gene

    eukaryotic translation elongation factor 1 gamma pseudogene 5


  • Gene

    importin 8 pseudogene 1


  • Gene

    MSI2 antisense RNA 1


  • Gene

    ANKRD33B pseudogene 9


  • Gene

    ribosomal protein L31 pseudogene 52

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.